Show simple item record

FieldValueLanguage
dc.contributor.authorTong, Allisonen
dc.contributor.authorElliott, Julian Hen
dc.contributor.authorAzevedo, Luciano Cesaren
dc.contributor.authorBaumgart, Amandaen
dc.contributor.authorBersten, Andrewen
dc.contributor.authorCervantes, Liliaen
dc.contributor.authorChew, Derek Pen
dc.contributor.authorCho, Yeoungjeeen
dc.contributor.authorCooper, Tessen
dc.contributor.authorCrowe, Sallyen
dc.contributor.authorDouglas, Ivor Sen
dc.contributor.authorEvangelidis, Nicoleen
dc.contributor.authorFlemyng, Ellaen
dc.contributor.authorHannan, Elyssaen
dc.contributor.authorHorby, Peteren
dc.contributor.authorHowell, Martinen
dc.contributor.authorLee, Jaeheeen
dc.contributor.authorLiu, Emmaen
dc.contributor.authorLorca, Eduardoen
dc.contributor.authorLynch, Deenaen
dc.contributor.authorMarshall, John Cen
dc.contributor.authorMatus Gonzalez, Andreaen
dc.contributor.authorMcKenzie, Anneen
dc.contributor.authorManera, Karine Een
dc.contributor.authorMcLeod, Charlieen
dc.contributor.authorMehta, Sangeetaen
dc.contributor.authorMer, Mervynen
dc.contributor.authorConway Morris, Andrewen
dc.contributor.authorNseir, Saaden
dc.contributor.authorPovoa, Pedroen
dc.contributor.authorReid, Marken
dc.contributor.authorSakr, Yasseren
dc.contributor.authorShen, Ningen
dc.contributor.authorSmyth, Alan Ren
dc.contributor.authorSnelling, Tomen
dc.contributor.authorStrippoli, Giovanni Fmen
dc.contributor.authorTeixeira-Pinto, Armandoen
dc.contributor.authorTorres, Antonien
dc.contributor.authorTurner, Tarien
dc.contributor.authorViecelli, Andrea Ken
dc.contributor.authorWebb, Steveen
dc.contributor.authorWilliamson, Paula Ren
dc.contributor.authorWoc-Colburn, Lailaen
dc.contributor.authorZhang, Junhuaen
dc.contributor.authorCraig, Jonathan Cen
dc.date.accessioned2020-09-14
dc.date.available2020-09-14
dc.date.issued2020en
dc.identifier.urihttps://hdl.handle.net/2123/23337
dc.description.abstractOBJECTIVES: The outcomes reported in trials in coronavirus disease 2019 are extremely heterogeneous and of uncertain patient relevance, limiting their applicability for clinical decision-making. The aim of this workshop was to establish a core outcomes set for trials in people with suspected or confirmed coronavirus disease 2019. DESIGN: Four international online multistakeholder consensus workshops were convened to discuss proposed core outcomes for trials in people with suspected or confirmed coronavirus disease 2019, informed by a survey involving 9,289 respondents from 111 countries. The transcripts were analyzed thematically. The workshop recommendations were used to finalize the core outcomes set. SETTING: International. SUBJECTS: Adults 18 years old and over with confirmed or suspected coronavirus disease 2019, their family members, members of the general public and health professionals (including clinicians, policy makers, regulators, funders, researchers). INTERVENTIONS: None. MEASUREMENTS: None. MAIN RESULTS: Six themes were identified. "Responding to the critical and acute health crisis" reflected the immediate focus on saving lives and preventing life-threatening complications that underpinned the high prioritization of mortality, respiratory failure, and multiple organ failure. "Capturing different settings of care" highlighted the need to minimize the burden on hospitals and to acknowledge outcomes in community settings. "Encompassing the full trajectory and severity of disease" was addressing longer term impacts and the full spectrum of illness (e.g. shortness of breath and recovery). "Distinguishing overlap, correlation and collinearity" meant recognizing that symptoms such as shortness of breath had distinct value and minimizing overlap (e.g. lung function and pneumonia were on the continuum toward respiratory failure). "Recognizing adverse events" refers to the potential harms of new and evolving interventions. "Being cognizant of family and psychosocial wellbeing" reflected the pervasive impacts of coronavirus disease 2019. CONCLUSIONS: Mortality, respiratory failure, multiple organ failure, shortness of breath, and recovery are critically important outcomes to be consistently reported in coronavirus disease 2019 trials.en
dc.language.isoenen
dc.rightsOther
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titleCore Outcomes Set for Trials in People With Coronavirus Disease 2019.en
dc.typeArticleen
dc.identifier.doi10.1097/ccm.0000000000004585
usyd.facultyFaculty of Medicine and Health, Sydney Medical Schoolen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.